Last reviewed · How we verify
Fuzuloparib , Abiraterone acetate and Prednisone
Fuzuloparib , Abiraterone acetate and Prednisone is a PARP inhibitor (fuzuloparib) combined with CYP17A1 inhibitor (abiraterone acetate) and glucocorticoid (prednisone) Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair deficiency. Also known as: SHR3162.
This combination uses fuzuloparib (a PARP inhibitor) to block DNA repair, combined with abiraterone acetate and prednisone to suppress androgen production and signaling in castration-resistant prostate cancer.
This combination uses fuzuloparib (a PARP inhibitor) to block DNA repair, combined with abiraterone acetate and prednisone to suppress androgen production and signaling in castration-resistant prostate cancer. Used for Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair deficiency.
At a glance
| Generic name | Fuzuloparib , Abiraterone acetate and Prednisone |
|---|---|
| Also known as | SHR3162 |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | PARP inhibitor (fuzuloparib) combined with CYP17A1 inhibitor (abiraterone acetate) and glucocorticoid (prednisone) |
| Target | PARP1/PARP2 (fuzuloparib); CYP17A1 (abiraterone acetate); glucocorticoid receptor (prednisone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Fuzuloparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair and inducing synthetic lethality in homologous recombination-deficient tumors. Abiraterone acetate blocks CYP17A1 to reduce intratumoral androgen synthesis, while prednisone provides glucocorticoid replacement and anti-inflammatory effects. Together, this triple combination targets both DNA repair deficiency and androgen signaling pathways in advanced prostate cancer.
Approved indications
- Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair deficiency
Common side effects
- Anemia
- Hypokalemia
- Hypertension
- Fatigue
- Nausea
- Diarrhea
- Myelosuppression
Key clinical trials
- Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC (PHASE2)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fuzuloparib , Abiraterone acetate and Prednisone CI brief — competitive landscape report
- Fuzuloparib , Abiraterone acetate and Prednisone updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about Fuzuloparib , Abiraterone acetate and Prednisone
What is Fuzuloparib , Abiraterone acetate and Prednisone?
How does Fuzuloparib , Abiraterone acetate and Prednisone work?
What is Fuzuloparib , Abiraterone acetate and Prednisone used for?
Who makes Fuzuloparib , Abiraterone acetate and Prednisone?
Is Fuzuloparib , Abiraterone acetate and Prednisone also known as anything else?
What drug class is Fuzuloparib , Abiraterone acetate and Prednisone in?
What development phase is Fuzuloparib , Abiraterone acetate and Prednisone in?
What are the side effects of Fuzuloparib , Abiraterone acetate and Prednisone?
What does Fuzuloparib , Abiraterone acetate and Prednisone target?
Related
- Drug class: All PARP inhibitor (fuzuloparib) combined with CYP17A1 inhibitor (abiraterone acetate) and glucocorticoid (prednisone) drugs
- Target: All drugs targeting PARP1/PARP2 (fuzuloparib); CYP17A1 (abiraterone acetate); glucocorticoid receptor (prednisone)
- Manufacturer: Jiangsu HengRui Medicine Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair deficiency
- Also known as: SHR3162